FeesSafety
Pluang+

OppFi stock drops over 34% despite strong free cash flow and buybacks, seen as undervalued with risks priced in.

Analyst Insights
10 Nov 2026, 17:49 WIB
Seeking Alpha
View Source
Bullish
OppFi stock drops over 34% despite strong free cash flow and buybacks, seen as undervalued with risks priced in.

OppFi Inc. has seen its stock price fall more than 34% in the past year amid declining core business metrics such as revenue and income, and higher charge-off rates. However, the company’s free cash flow surged by 63%, supported by ongoing share buybacks. Recent challenges include a withdrawn acquisition and lowered guidance, but these risks appear to be reflected in the current stock valuation. This suggests OppFi could be an undervalued opportunity in the financial sector if it manages regulatory and competitive risks effectively.

OppFi's recent financial challenges provide context for the broader Financials sector on Pluang. As of Nov 10, 2026 22:31 WIB, out of 142 priced Financials-sector US stocks, 54 rose and 87 fell. Notable movers include AVAT with a price of USD 1.05 and a 1-day gain of 15.45%, MARA at USD 7.51 up 13.10%, and UPST at USD 20.52 down 7.80%, with UPST showing a full 100% buy order activity and the longest typical hold time of 40 days among these.

More News

Science 37 named BioSpace 2027 Best Place to Work for innovative clinical trial model and culture

Science 37 named BioSpace 2027 Best Place to Work for innovative clinical trial model and culture

Science 37, a direct-to-patient clinical research site, was named a BioSpace 2027 Best Place to Work, recognized for its innovative culture and commitment to clinical quality. The company’s model brings clinical trials to patients' homes, improving a...

Others
Bullish
1 hour ago
Peptide therapeutics market to hit $229B by 2036, driven by GLP-1, oncology, and generics growth

Peptide therapeutics market to hit $229B by 2036, driven by GLP-1, oncology, and generics growth

The global peptide therapeutics market is projected to grow from $112.2 billion in 2026 to $229.32 billion by 2036, at a CAGR of 7.4%. Growth is fueled by expanding use of GLP-1 and incretin therapies, advances in peptide engineering, new oncology ap...

Bullish
1 hour ago
New AI tool Book Leopard cuts Amazon book marketing costs to under $50 with fast, quality covers and ads.

New AI tool Book Leopard cuts Amazon book marketing costs to under $50 with fast, quality covers and ads.

Book Leopard, a new AI software, enables authors and publishers to create professional-quality Amazon book marketing materials in seconds for a one-time fee of $49, drastically reducing costs from over $1,000 and weeks of waiting. The tool generates ...

Others
Bullish
2 hours ago
Global nucleic acid labeling market to hit $2.8B by 2032, driven by genomics and diagnostics growth.

Global nucleic acid labeling market to hit $2.8B by 2032, driven by genomics and diagnostics growth.

The global nucleic acid labeling market, valued at $1.7 billion in 2025, is projected to grow to $2.8 billion by 2032 at a 7% CAGR. Growth is fueled by advances in genomics, molecular diagnostics, and personalized medicine, with increasing demand for...

Market News
Bullish
2 hours ago
MonetizeMore launches AI tool to help publishers avoid Google AdSense bans.

MonetizeMore launches AI tool to help publishers avoid Google AdSense bans.

MonetizeMore introduced the AdSense Policy Grader, an AI-powered tool that audits websites for compliance with Google's ad policies to prevent account bans and revenue loss. The tool offers a free basic report and a detailed paid report covering 79 p...

Others
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App